No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
MBRX Moleculin Biotech
- 4.1400
- -0.2100-4.83%
Close Jun 14 16:00 ET
- 4.2700
- +0.1300+3.14%
Post 19:59 ET
9.57MMarket Cap-319P/E (TTM)
4.9000High3.8400Low190.67KVolume4.6100Open4.3500Pre Close898.18KTurnover9.16%Turnover RatioLossP/E (Static)2.31MShares15.750052wk High0.44P/B8.62MFloat Cap3.840052wk Low--Dividend TTM2.08MShs Float731.7000Historical High--Div YieldTTM24.37%Amplitude3.8400Historical Low4.7100Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $20
Maxim Group analyst Jason McCarthy maintains $Moleculin Biotech(MBRX.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 29.1% a
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersAinos (NASDAQ:AIMD) stock rose 54.8% to $1.27 during Friday's pre-market session. The market value of their outstanding shares is at $8.2 million. Longeveron (NASDAQ:LGVN) shares moved upwards
Express News | Moleculin Biotech Inc: Recruitment Increased to 22 Subjects and Crc's in All Subjects Evaluable for Efficacy (N=20) Was 45% in Study
Express News | Moleculin Biotech Inc: Annamycin Continues to Demonstrate No Cardiotoxicity
Express News | Moleculin Biotech Inc: Current Median Durability of Response (Mdor) of Crc's = 6 Months and Increasing (N=9) in Study
Express News | Moleculin Biotech Inc: 89% Of Crc's Were Subjects With "Poor Prognosis" Cytogenetics and/or Mutations in Study
Comments
$Moleculin Biotech(MBRX.US$ Moleculin Announces Additional Positive Preliminary Interim Data From Aml Clinical Trial! 89% Of Crc's Were Subjects With "Poor Prognosis" Cytogenetics and/or Mutations in Study! Annamycin Continues to Demonstrate No Cardiotoxicity! Current Median Durability of Response (Mdor) of Crc's = 6 Months and Increasing (N=9) in Study
$Moleculin Biotech(MBRX.US$ Means the stock will go on a run soon which will then be stopped by adding shares. If you buy you might wanf try to sell before it reaches 30% gains.
4
$Moleculin Biotech(MBRX.US$ Moleculin Announces Commencement of Nih-Funded Phase 2 Clinical Trial of Stat3 Inhibitor for the Treatment of Glioblastoma (Nu 21C06)
$Moleculin Biotech(MBRX.US$ Reuters· 1 min ago
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
1
$Moleculin Biotech(MBRX.US$
NEWS
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
The issuance of the U.S. Patent for Lipid-Based Delivery Technology for Annamycin provides composition protection until 2040, with the potential for extension, enhancing the Company's intellectual property portfolio.
Annamycin, the next-generation anthracycline developed by Moleculin, has demonstrated promising results in clinical studies, showing non-cardiotoxic...
NEWS
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
The issuance of the U.S. Patent for Lipid-Based Delivery Technology for Annamycin provides composition protection until 2040, with the potential for extension, enhancing the Company's intellectual property portfolio.
Annamycin, the next-generation anthracycline developed by Moleculin, has demonstrated promising results in clinical studies, showing non-cardiotoxic...
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg